Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population: a population-based survey.

@article{YamakawaKobayashi1999FrequentOO,
  title={Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population: a population-based survey.},
  author={Kimiko Yamakawa‐Kobayashi and Hisako Yanagi and Haruhisa Fukayama and Chiaki Hirano and Yae Shimakura and Naomasa Yamamoto and Tadao Arinami and Shigeru Tsuchiya and Hideo Hamaguchi},
  journal={Human molecular genetics},
  year={1999},
  volume={8 2},
  pages={
          331-6
        }
}
To determine the frequency of familial hypoalphalipoproteinemia in the general population due to mutation of the apolipoprotein A-I (apo A-I) gene, we analyzed sequence variations in the apo A-I gene. The subjects were 67 children with a low high-density lipoprotein (HDL) cholesterol level (</=38 mg/dl, below the fifth percentile in the population of this study) who were screened from 1254 schoolchildren through a school survey. Four different mutations with deleterious potential, three… 
Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency.
TLDR
Haplotype analysis performed using several polymorphisms suggested that both the c.85 del C and L141R are likely to be recurrent mutations.
Apolipoprotein A-I Mutations
TLDR
The identification of individuals homozygous for mutations of the Apolipoprotein A-I gene, leading to severe ApoA-I deficiency, is very useful for better understanding of the roles of Apo-I and HDL in protection against CAD.
Analysis of apolipoprotein A-I, lecithin:cholesterol acyltransferase and glucocerebrosidase genes in hypoalphalipoproteinemia.
TLDR
12% of HALP subjects were found to carry mutations in apo A-I, LCAT, or GBA genes, which could explain this phenotype, and results confirm the molecular, genetic and phenotypic heterogeneity of HALp.
Apolipoprotein A-I Mutations and Clinical Evaluation
TLDR
Analyses of the apoA-I amino acid sequence have revealed that most of its 243 amino acid residues are grouped into amphipathic α-helices of 11 or 22 amino acids in length, which reduces the ability of the protein to solubilize lipid.
The effects of altered apolipoprotein A-I structure on plasma HDL concentration.
TLDR
Observations strongly support the idea that the tertiary structure of apoA-I determines its intravascular fate and ultimately the steady state concentration of plasma HDL.
Evidence of linkage of familial hypoalphalipoproteinemia to a novel locus on chromosome 11q23.
TLDR
This study assesses the evidence for linkage of low HDL-C to chromosomal region 11q23 in 105 large Utah pedigrees ascertained with closely related clusters of early CHD and expanded on the basis of dyslipidemia.
Genetic Etiology of Isolated Low HDL Syndrome: Incidence and Heterogeneity of Efflux Defects
TLDR
Efflux defects are frequent in low HDL syndromes, but the majority of HDL deficient subjects with cellular cholesterol efflux defects do not harbor ABCA1 mutations, suggesting that novel pathways contribute to this phenotype.
A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production.
TLDR
A novel apolipoprotein (apo) A-I truncation due to a heterozygous nonsense mutation in a 68-year-old male proband with premature coronary heart disease, corneal arcus, and very low plasma concentrations of HDL cholesterol (HDL-C) and apoA-I is reported.
Proteolytic Degradation and Impaired Secretion of an Apolipoprotein A-I Mutant Associated with Dominantly Inherited Hypoalphalipoproteinemia*
TLDR
This is the first demonstration of an apoA-I point mutation that decreases LCAT activation, impairs hepatocyte secretion of apo-I, and makes apo A-I susceptible to proteolysis leading to dominantly inherited hypoalphalipoproteinemia.
Gene-drug interaction: additive influence of mutant APOA1 and testosterone on plasma HDL-cholesterol.
TLDR
The findings suggest that the low plasma HDL cholesterol associated with heterozygosity for mutant APOA1 can become extremely depressed during treatment with oral or intramuscular androgens, and suggests that transdermal testosterone may perturb HDL to a lesser extent than other routes of delivery in such patients.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Apolipoprotein A-IFin. Dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene.
TLDR
A novel point mutation of the APO A-I gene, apo A-IFin, is described, causing a dominantly negative phenotype as regards serum HDL levels, possibly due to increased catabolism of apoA-I.
Autosomal dominant hypoalphalipoproteinemia due to a completely defective apolipoprotein A-I gene.
TLDR
The data suggest that a part of familial hypoalphalipoproteinemia might be an autosomal dominant trait due to a completely defective apolipoprotein A-I gene.
A novel homozygous missense mutation in the apo A-I gene with apo A-I deficiency.
TLDR
The genetic defect in a 67-year-old Japanese male patient with apolipoprotein (apo) A-I and high density lipoprotein (HDL) deficiencies, corneal opacities, and coronary artery disease is analyzed and it is suggested that the Val156Glu substitution is associated with apoA- I and HDL deficiency, partial LCAT deficiency, and cornealsugar deficiency.
Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene.
TLDR
Findings indicate that homozygosity for the apoA-I gene with codon 84 nonsense mutation causes the deficiency of apolipoprotein A-I and of high density lipoprotein cholesterol in the patient.
Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease.
TLDR
Apo A-I deficiency may lead to premature atherosclerosis if present in conjunction with additional cardiovascular risk factors, including elevated LDL cholesterol levels, obesity, and arterial hypertension.
The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano.
TLDR
A French patient who presented with very low serum HDL-cholesterol levels is described, and a heterozygous mutation in the apo A-I gene is identified which causes a cysteine for arginine replacement at residue 151, causing a phenocopy of api A-IMilano (R173C), an apo C-I variant which is assumed to cause longevity and which is considered as a potentially anti-atherogenic agent.
Heterozygosity for apolipoprotein A-I(R160L)Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I.
TLDR
It is concluded that the failure of apoA-1 (R160L)Oslo to form LpA-I/A-II causes low HDL-cholesterol in heterozygous carriers of this apo A-I variant.
A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and periorbital xanthelasmas.
TLDR
Despite half-normal plasma concentrations of HDL cholesterol and apoA-I in subjects heterozygous for this mutation, the history of the patient's large family did not indicate any increased prevalence of myocardial infarction.
Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia.
TLDR
A Canadian kindred with a novel mutation in the apolipoprotein (apo) A-I gene causing analphalipoproteinemia appears to be at significantly increased risk for atherosclerosis.
A new case of apoA-I deficiency showing codon 8 nonsense mutation of the apoA-I gene without evidence of coronary heart disease.
TLDR
A 39-year-old Japanese man with HDL and apoA-I deficiency without evidence of coronary heart disease and the results of a pedigree analysis by DNA sequencing and restricted fragment length polymorphism were consistent with an autosomal codominant trait.
...
1
2
3
4
...